ES2543804T3 - Polimorfo B de Ibandronato - Google Patents

Polimorfo B de Ibandronato Download PDF

Info

Publication number
ES2543804T3
ES2543804T3 ES06701843.2T ES06701843T ES2543804T3 ES 2543804 T3 ES2543804 T3 ES 2543804T3 ES 06701843 T ES06701843 T ES 06701843T ES 2543804 T3 ES2543804 T3 ES 2543804T3
Authority
ES
Spain
Prior art keywords
hydroxypropane
pentyl
acetone
amino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06701843.2T
Other languages
English (en)
Inventor
Uwe Eiermann
Bernd Junghans
Bernhard Knipp
Tim Sattelkau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36088250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2543804(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2543804T3 publication Critical patent/ES2543804T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Procedimiento para la preparación de un polimorfo cristalino de monohidrato de sal monosódica (Ibandronato) del ácido 3-(N-metil-N-pentil) amino-1-hidroxipropano-1,1-difosfónico que se caracteriza con un patrón de difracción de rayos X de polvos, teniendo los picos característicos que se expresan en el ángulo 2-theta a aproximadamente +- 0,2 grados Ángulo 2-theta 9,7º 12,2º 14,4º 16,8º 25,8º que comprende la cristalización de sal monosódica del ácido 3-(N-metil-N-pentil) amino-1-hidroxipropano-1,1- difosfónico o un monohidrato, un polimorfo o una mezcla de los mimos polimorfos a una temperatura de 10°C a 45°C en un solvente polar que es agua y con la adición de un solvente aprótico polar que es acetona para iniciar la cristalización, en donde el precipitado se lava con una mezcla de agua y acetona en una proporción de aproximadamente 1:1 (V/V).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES06701843.2T 2005-02-01 2006-01-24 Polimorfo B de Ibandronato Active ES2543804T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100687 2005-02-01
EP05100687 2005-02-01
PCT/EP2006/000579 WO2006081962A1 (en) 2005-02-01 2006-01-24 Ibandronate polymorph b

Publications (1)

Publication Number Publication Date
ES2543804T3 true ES2543804T3 (es) 2015-08-24

Family

ID=36088250

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06701843.2T Active ES2543804T3 (es) 2005-02-01 2006-01-24 Polimorfo B de Ibandronato

Country Status (20)

Country Link
US (2) US7582789B2 (es)
EP (3) EP1848727B1 (es)
JP (2) JP5828607B2 (es)
KR (1) KR100908530B1 (es)
CN (1) CN101111505B (es)
AR (1) AR053119A1 (es)
AU (1) AU2006210008B2 (es)
BR (1) BRPI0607093A2 (es)
CA (1) CA2594717C (es)
DK (1) DK1848727T3 (es)
ES (1) ES2543804T3 (es)
IL (1) IL184720A (es)
MX (1) MX2007008917A (es)
NO (1) NO20073755L (es)
PL (1) PL1848727T3 (es)
RU (1) RU2387661C2 (es)
SI (1) SI1848727T1 (es)
TW (1) TWI374888B (es)
WO (1) WO2006081962A1 (es)
ZA (1) ZA200706170B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090120011A (ko) 2004-08-23 2009-11-23 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
PL1848727T3 (pl) 2005-02-01 2015-11-30 Hoffmann La Roche Polimorf b ibandronianu
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
PT103600B (pt) * 2006-11-06 2009-01-30 Hovione Farmaciencia Sa Processo para a preparação de ácidos biosfónicos e seus sais farmaceuticamente aceitáveis
US20090012047A1 (en) * 2006-11-16 2009-01-08 Eran Turgeman Crystalline forms of ibandronate sodium
US7662990B2 (en) * 2007-04-11 2010-02-16 Hoffmann-La Roche Inc. Process for preparing ibandronate
NZ580042A (en) * 2007-04-19 2011-12-22 Reddys Lab Inc Dr Ibandronate sodium polymorphs
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
WO2009053445A2 (en) * 2007-10-26 2009-04-30 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
WO2012007021A1 (en) 2010-07-14 2012-01-19 Pharmathen S.A. Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
TR201200588A2 (tr) 2012-01-18 2012-07-23 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
KR20200085441A (ko) 2019-01-07 2020-07-15 엠에프씨 주식회사 이반드로네이트의 신규한 결정형 및 이의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764604A (en) * 1968-12-17 1973-10-09 Us Army 4-pyridylcarbinolamine anti-malarials
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
TW198039B (es) * 1988-11-28 1993-01-11 Ciba Geigy Ag
AU8229291A (en) * 1990-07-10 1992-02-04 Smithkline Beecham Corporation Oxamides
DE19531264A1 (de) * 1995-08-25 1997-02-27 Hoechst Ag Kationische, ungesättigte Saccharide sowie daraus hergestellte Polymerisate und deren Verwendung
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
DE69907495T2 (de) 1998-10-16 2004-05-06 Akzo Nobel N.V. (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5-(10)-en-20-yn-3-on als reine verbindung
WO2000033849A1 (en) * 1998-12-04 2000-06-15 Roche Diagnostics Gmbh Use of ibandronate for promoting osseointegration of endoprostheses
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
AU2001251122A1 (en) * 2000-03-30 2001-10-15 Research Development Foundation Tyr393 and tyr398 mutants of monoamine oxidase b
CN1404836A (zh) * 2001-09-14 2003-03-26 中生北方生物工程开发研究所 埃本膦酸钠作为预防和治疗骨质疏松症的药物的有效成分的应用
CN1939314A (zh) * 2002-05-10 2007-04-04 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
KR20090120011A (ko) * 2004-08-23 2009-11-23 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
PL1848727T3 (pl) * 2005-02-01 2015-11-30 Hoffmann La Roche Polimorf b ibandronianu
CN101111504B (zh) * 2005-02-01 2011-12-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物a

Also Published As

Publication number Publication date
JP6039755B2 (ja) 2016-12-07
JP2015205908A (ja) 2015-11-19
WO2006081962A1 (en) 2006-08-10
EP1848727B1 (en) 2015-06-17
CA2594717C (en) 2015-01-20
AU2006210008A1 (en) 2006-08-10
IL184720A0 (en) 2007-12-03
TW200640940A (en) 2006-12-01
ZA200706170B (en) 2008-09-25
TWI374888B (en) 2012-10-21
US20060172976A1 (en) 2006-08-03
DK1848727T3 (da) 2015-07-20
AU2006210008B2 (en) 2009-10-08
CN101111505A (zh) 2008-01-23
KR100908530B1 (ko) 2009-07-20
JP5828607B2 (ja) 2015-12-09
JP2008531480A (ja) 2008-08-14
EP1848727A1 (en) 2007-10-31
AR053119A1 (es) 2007-04-25
MX2007008917A (es) 2007-08-21
EP2363401A1 (en) 2011-09-07
RU2387661C2 (ru) 2010-04-27
NO20073755L (no) 2007-08-28
CA2594717A1 (en) 2006-08-10
EP2610261A1 (en) 2013-07-03
BRPI0607093A2 (pt) 2009-08-04
US20090312289A1 (en) 2009-12-17
SI1848727T1 (sl) 2015-09-30
IL184720A (en) 2014-12-31
CN101111505B (zh) 2011-09-14
KR20070100395A (ko) 2007-10-10
PL1848727T3 (pl) 2015-11-30
RU2007132700A (ru) 2009-03-10
US7582789B2 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
ES2543804T3 (es) Polimorfo B de Ibandronato
HRP20140395T1 (hr) SPOJEVI PIROLO[2,3-d]PIRIMIDINA
AR071246A1 (es) Proceso para la preparacion de compuestos utiles como inhibidores de sglt
ES2660773T3 (es) Procedimiento para la preparación de una sal cristalina trialcalino-metálica de L-MGDA
AR098260A2 (es) Polimorfo cristalino de una sal de bisulfato de un antagonista del receptor de trombina, proceso para su preparación, composición y forma purificada
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
HRP20210748T1 (hr) Postupak priprave spojeva s aktivnošću inhibitora hiv integraze
ES2577303T3 (es) Procedimientos para la preparación de la forma polimórfica I de hidrogenosulfato de clopidogrel
TWI546311B (zh) 固殺草ｐ游離酸之製造方法
HRP20170540T1 (hr) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
CA2594802A1 (en) Ibandronate polymorph a
HRP20141120T1 (hr) Furazanobenzimidazoli kao predlijekovi za lijeäśenje neoplastiäśnih ili autoimunih bolesti
HRP20130950T1 (hr) Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina
ES2613716T3 (es) Formas cristalinas de un derivado de purina
JP6160621B2 (ja) ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物
NZ570533A (en) Compounds useful as Selective androgen receptor modulators (SARM), in particular (2S)-3-(4-cyano-3-fluorophenoxy)-N-(4-cyano-3-methylphenyl)-2-hydroxy-2-methylpropionamide useful in hormonal therapy
HRP20100357T1 (hr) Beta-kristalni oblik soli perindoprilarginina, postupak njegove priprave i farmaceutske smjese koje ga sadrže
CO6241155A2 (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo
RU2016106125A (ru) Соли дасатиниба в кристаллической форме
HRP20170023T1 (hr) Kristalni oblik pemirolasta
ES2548269T3 (es) Nueva forma cristalina de un inhibidor de la DPP-IV
PE20070548A1 (es) Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
HRP20131164T1 (hr) Delta kristalni oblik argininske soli perindoprila, postupak za njegovu pripremu i farmaceutske pripravke koji ga sadrže
AR085171A1 (es) Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene
RU2016134404A (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ